Tracey Ikerd, MD
Infectious Disease · Carmel, INNPI 1871532234
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,250 of the $39,407 with a category attached, or 74.2%. AbbVie accounts for 83.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $8,450 and has fallen 58.0% since, to $3,546 in 2025. Among infectious disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $231.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Organogenesis Inc.$2K
- Merz North America, Inc.$937
- La Jolla Pharmaceutical Company$549
- Urgo Medical North America, LLC$528
- Smith+Nephew$424
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$29,25074%
- Grants$4501%
- Travel & lodging$9602%
- Food & beverage$8,70722%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $32,786 |
| Organogenesis Inc. | 16 | $1,695 |
| Merz North America, Inc. | 4 | $937 |
| La Jolla Pharmaceutical Company | 5 | $549 |
| Urgo Medical North America, LLC | 3 | $528 |
| Smith+Nephew | 7 | $424 |
| Kerecis Limited | 3 | $264 |
| Paratek Pharmaceuticals, Inc. | 4 | $196 |
| Merck | 12 | $150 |
| Stryker | 1 | $147 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $146 |
| Integra Lifesciences Corporation | 2 | $144 |
| Johnson & Johnson | 9 | $138 |
| Cardiovascular Systems Inc. | 1 | $136 |
| Misonix Inc | 1 | $125 |
| Convatec Inc. | 1 | $124 |
| Tactile Systems Technology Inc | 3 | $124 |
| Angiodynamics, Inc. | 1 | $121 |
| Viiv Healthcare Company | 7 | $106 |
| Janssen Products, LP | 1 | $102 |
| Revance Therapeutics, Inc. | 1 | $67 |
| Melinta Therapeutics, LLC | 3 | $61 |
| Insmed, Inc. | 3 | $56 |
| Gilead | 4 | $54 |
| Terumo Medical Corporation | 1 | $53 |
| Mayne Pharma Commercial LLC | 2 | $35 |
| Theratechnologies Inc. | 2 | $32 |
| Invivyd Inc | 1 | $25 |
| Solventum Corporation | 1 | $20 |
| Mimedx Group, Inc. | 1 | $19 |
| CSL Behring | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Osiris Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DALVANCE$28,580
- AVYCAZ$2,105
- PuraPly$1,162
- TEFLARO$1,035
- XEOMIN$898
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$329
- Kerecis Omega3 Wound$218
- Kerecis Omega3 Surgibind$218
- Kerecis Omega3 GraftGuide$218
- Kerecis Omega3 SurgiClose$218
- URGOCLEAN AG$199
- Apligraf$151
- FLOWTRIEVER CATHETER, S$147
- CT THROMBECTOMY SYSTEM KIT$147
- DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$145
- UrgoK2$145
- GRAFIX PL$143
- NuShield$138
- Diamondback Peripheral$136
- Zevtera$131
How this compares
$39,407 in reported general payments places this provider in the 95th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 106 | $458,099 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 34 | $127,666 |
| IsentressRaltegravir Potassium | 24 | $51,085 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $45,958 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $43,058 |
| Etravirine | 25 | $23,253 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $11,101 |
| Darunavir | 12 | $4,016 |
| Efavirenz | 12 | $3,474 |
| Vancomycin Hcl | 15 | $3,309 |
| Fosfomycin Tromethamine | 12 | $3,064 |
| Cefadroxil | 46 | $2,436 |
| Cephalexin | 41 | $1,235 |
| ValacyclovirValacyclovir Hcl | 34 | $1,177 |
| CefuroximeCefuroxime Axetil | 23 | $899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $54 | $504,057117 claims |
| Viiv Healthcare CompanyTriumeq, Dovato | $106 | $170,72349 claims |
| MerckIsentress | $150 | $51,08524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Carmel
- Markian BochanCarmel$54K
- Francisco DelgadoCarmel$3K
- Joshua BergCarmel$1K
- Chad TewellCarmel$1K
- Hassan ElmalikCarmel$1K
- Joseph FraizCarmel$676
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.